Cargando…

Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4

BACKGROUND: Neratinib is in Phase 3 clinical trials but, unfortunately, the development of resistance is inevitable. Here, we investigated the effects of acquired neratinib resistance on cellular phenotype and the potential mechanism of this resistance. METHODS: Neratinib-resistant variants of HER2-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Breslin, Susan, Lowry, Michelle C, O'Driscoll, Lorraine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Translational Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344284/ https://www.ncbi.nlm.nih.gov/pubmed/28152547 http://dx.doi.org/10.1038/bjc.2016.445

Ejemplares similares

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
por: Cummings, J, et al.
Publicado: (2012)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Src, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
por: Peiró, G, et al.
Publicado: (2014)

ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
por: Vaidyanathan, Aparajitha, et al.
Publicado: (2016)

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
por: Yokoyama, H, et al.
Publicado: (2006)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells
por: Agarwal, S, et al.
Publicado: (2009)

Characterisations of human prostate stem cells reveal deficiency in class I UGT enzymes as a novel mechanism for castration-resistant prostate cancer
por: Williamson, S C, et al.
Publicado: (2013)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance
por: Breslin, Susan, et al.
Publicado: (2016)

Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer
por: Mittal, Karuna, et al.
Publicado: (2017)

EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
por: Evans, A H, et al.
Publicado: (2010)

Modulation of erlotinib pharmacokinetics in mice by a novel cytochrome P450 3A4 inhibitor, BAS 100
por: Smith, N F, et al.
Publicado: (2008)

Caspase-dependent and -independent suppression of apoptosis by monoHER in Doxorubicin treated cells
por: Bruynzeel, A M E, et al.
Publicado: (2007)

HER2 expression as a potential marker for response to therapy targeted to the EGFR
por: Emlet, D R, et al.
Publicado: (2006)

Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma
por: De Silva, Nadeera, et al.
Publicado: (2015)

HER2 expression patterns in paired primary and metastatic endometrial cancer lesions
por: Halle, Mari Kyllesø, et al.
Publicado: (2018)

Combined modalities of resistance in an oxaliplatin-resistant human gastric cancer cell line with enhanced sensitivity to 5-fluorouracil
por: Chen, C-C, et al.
Publicado: (2007)

EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy
por: Kumai, T, et al.
Publicado: (2013)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies
por: Tural, D, et al.
Publicado: (2014)

Anti-HER-2 DNA vaccine protects Syrian hamsters against squamous cell carcinomas
por: Berta, G N, et al.
Publicado: (2005)

Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma
por: Kawaguchi, Y, et al.
Publicado: (2007)

Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab
por: Todeschini, P, et al.
Publicado: (2011)

Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014)

Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies
por: Laux, I, et al.
Publicado: (2006)

Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice
por: Bruynzeel, A M E, et al.
Publicado: (2007)

Human responses against HER-2-positive cancer cells in human immune system-engrafted mice
por: De Giovanni, C, et al.
Publicado: (2012)

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer
por: Schmidt, M, et al.
Publicado: (2007)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells
por: Konecny, G E, et al.
Publicado: (2008)

Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
por: Lee, H J, et al.
Publicado: (2015)

Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo
por: Schwab, C L, et al.
Publicado: (2014)

Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles
por: Martinez, Vanesa G., et al.
Publicado: (2017)

Combined effects of GSTP1 and MRP1 in melanoma drug resistance
por: Depeille, P, et al.
Publicado: (2005)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer
por: Shen, Y, et al.
Publicado: (2013)

Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin
por: Colmegna, B, et al.
Publicado: (2015)

Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy
por: Pisanu, M E, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4qn1c48eds4io1c19s9d1cjga4